Acute bacterial otitis media
0 original drugs 0
Novel Drugs
6
Reformulations
0
Active Trials
0
Drug Targets
Acute bacterial otitis media has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Precision Medicine Biomarkers
All biomarkers →Biomarkers used for patient selection in Acute bacterial otitis media
Novel Acute bacterial otitis media Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (6 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
Generic Drugs (8 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs